Browse
Submit Data
Databases
API
Help

Dataset Information

31 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

An exploratory study on optimizing the administration time of furquintinib combined with camrelizumab in the third-line treatment of MSS late colorectal cancer

ABSTRACT: Interventions: Test group:Camrelizumab + Fruquintinib Primary outcome(s): progression-free survival Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 2716835 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

An exploratory clinical study of camrelizumab combined with radiotherapy in the treatment of postoperative or late recurrence of colorectal cancer

Project description:Interventions: Test group :Camrelizumab + radiotherapy Primary outcome(s): Progression-free survival Study Design: Single arm

| 2760326 | ecrin-mdr-crc

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Project description:Limited agents are optional after standard first and second line treatment for mCRC. Nowadays, cancer therapy has entered the era of immunotherapy. The approved cancer therapies include pembrolizumab and nivolumab, but only for MSI-H patients. 95% of non MSI-H / dMMR patients with advanced colorectal cancer can not benefit from them. Therefore, the use of PD-1 / PD-L1 monoclonal antibody in mCRC is greatly limited. Our previous research showed that anti-PD-1 combined with Fruquintinib can significantly inhibit the growth of CRC in MSS mice. At the same time, a retrospective clinical study showed that patients with MSS CRC can benefit from Sintilimab combined with Fruquintinib. Camrelizumab is PD-1 monoclonal antibody, which has been approved for a variety of tumors. The prospective clinical trial of Camrelizumab combined with Fruquintinib may bring new hope for the treatment of non MSI-H / dMMR patients with mCRC.This study is aimed to explore the efficacy, safety in advanced colorectal cancer failed to standard therapy in Chinese population.

| 2375994 | ecrin-mdr-crc

Exploratory observational study of famitinib malate combined with carrillizumab in third-line and post-third-line treatment of colorectal cancer

Project description:Interventions: Single arm:camrelizumab combined with famitinib Primary outcome(s): Overall Survival Study Design: Single arm

| 2693365 | ecrin-mdr-crc

Recurrent Gallbladder Carcinoma With pMMR/MSS Achieved a Complete Response Following Camrelizumab Combined With Apatinib: A Case Report.

Project description:Gallbladder carcinoma (GBC) with proficient mismatch repair (pMMR)/microsatellite stable (MSS) is associated with limited response to programmed death-1 (PD-1) inhibitor monotherapy. Limited data of PD-1 blockade combined with anti-angiogenic therapy in GBC are reported. One recurrent GBC patient with pMMR/MSS was treated with camrelizumab plus apatinib. After 4 cycles of combination therapy, the patient achieved a durable complete response with manageable toxicity. The next-generation sequencing and immunohistochemistry analysis showed that tumor mutation burden (TMB) was 7.26 mutants/Mb and PD-L1 expression was 10% (tumor proportion score) and 20% (immune proportion score). This case suggests that camrelizumab in combination with apatinib may be an effective treatment option for GBC patients with pMMR/MSS status, who have moderate expression of TMB and PD-L1. Additionally, TMB and PD-L1 expression may serve as potential biomarkers for predicting PD-1 inhibitor response of GBC. Furthermore, this needs to be verified in future studies.

| S-EPMC8792461 | biostudies-literature

Camrelizumab combined with Apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer: single arm exploratory study

Project description:Interventions: Case series:Camrelizumab + Apatinib Primary outcome(s): Objective response rate Study Design: Single arm

| 2686078 | ecrin-mdr-crc

A double arm, prospective and exploratory phase II clinical study of Camrelizumab combined with or without bevacizumab / apatinib mesylate in the treatment of locally advanced rectal cancer

Project description:Interventions: control group:Camrelizumab;experimental group 1:Camrelizumab;experimental group:bevacizumab / apatinib Primary outcome(s): complete pathological response rate Study Design: Non randomized control

| 2759992 | ecrin-mdr-crc

A single-arm, prospective, open-label clinical study of camrelizumab combined with apatinib mesylate as a third-line treatment for advanced colorectal cancer

Project description:Interventions: single arm:camrelizumab combined with apatinib mesylate Primary outcome(s): PFS Study Design: Single arm

| 2690370 | ecrin-mdr-crc

Single-arm phase II exploratory study of cetuximab combined with camrelizumab in RAS wild-type recurrent or distantly metastatic advanced colorectal cancer after failure of second-line standard therapy

Project description:Interventions: Experimental group:Cetuximab:500mg/m2,d1,q2w Camrelizumab:200mg, d1, q2w Primary outcome(s): Objective response rate Study Design: Single arm

| 85219 | ecrin-mdr-crc

Clinical Trial of Camrelizumab Combined with Cetuximab and Chemotherapy Drugs to treat Ras Wild Colorectal Cancer

Project description:Interventions: 1:Camrelizumab, Cetuximab, and chemotherapeutics.;2:Camrelizumab, Cetuximab and chemotherapeutics. Primary outcome(s): ORR Study Design: Non randomized control

| 2688526 | ecrin-mdr-crc

Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer.

Project description:Colorectal cancer (CRC) is one of the most common malignancies, and at the initial visit, most patients are diagnosed with metastatic CRC (mCRC). However, immunotherapy is only and highly effective in a very small proportion of patients with mCRC having mismatch repair defect (dMMR)/high microsatellite instability, and the majority of the patients with mCRC having mismatch repair proficient (pMMR)/microsatellite stability (MSS) cannot benefit from it. At present, many clinical studies of immunotherapy combined with tyrosine kinase inhibitors (TKIs) are trying to regulate the immune microenvironment of pMMR/MSS mCRC, transforming a "cold tumor" into a "hot tumor," which has not only surprising effects but also certain limitations, i.e., the response could not be specific to metastasis. Therefore, regarding the bottleneck encountered by immunotherapy in patients with patients pMMR/MSS mCRC, this study summarized current research and possible mechanisms of immunotherapy combined with local therapy for metastasis, including radiotherapy, ablation, and transcatheter arterial chemoembolization.

| S-EPMC10695980 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data